Molecular Formula | C22H15NO4S2 |
Molar Mass | 421.49 |
Density | 1.50±0.1 g/cm3(Predicted) |
Boling Point | 634.7±65.0 °C(Predicted) |
Solubility | DMSO: soluble3mg/mL, clear (warmed) |
Appearance | powder |
Color | , yellow to orange to brown |
pKa | 4.11±0.10(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
In vitro study | Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.361 ml | 11.806 ml | 23.613 ml |
5 mM | 0.472 ml | 2.361 ml | 4.723 ml |
10 mM | 0.236 ml | 1.181 ml | 2.361 ml |
5 mM | 0.047 ml | 0.236 ml | 0.472 ml |
biological activity | Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/cd18. Leukadherin-1 increased the adhesion of CD11b/cd18-dependent cells to fibrinogen with an EC50 of 4 μm. Leukadherin-1 enhances leukocyte adhesion to the ligand (e. G., ICAM-1) and vascular endothelium, thereby reducing leukocyte transendothelial migration and influx to the site of injury. Leukadherin-1 inhibition of innate inflammatory signal transduction. |
Animal Model: | Newborn Sprague Dawley rat pups |
Dosage: | 1 mg/kg |
Administration: | I.p.; twice daily for 14 days |
Result: | Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD. |